Create Free Account

By creating account you will get access to hot stocks & personalised emails

Cyclopharm Ltd

Healthcare AU CYC

1.35AUD
-(-%)

Last update at 2024-11-13T05:10:00Z

Day Range

1.331.39
LowHigh

52 Week Range

1.352.20
LowHigh

Fundamentals

  • Previous Close 1.35
  • Market Cap159.48M
  • Volume29286
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-12.97738M
  • Revenue TTM24.06M
  • Revenue Per Share TTM0.25
  • Gross Profit TTM 17.41M
  • Diluted EPS TTM-0.1

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -6.02985M -4.34687M -5.84411M -2.42494M 0.12M
Minority interest - - - - -
Net income -6.61151M -5.04017M -6.04364M -2.91244M -0.03546M
Selling general administrative 10.96M 10.30M 9.47M 6.38M 5.88M
Selling and marketing expenses 2.92M 1.02M 0.85M 0.64M 0.76M
Gross profit 15.78M 12.66M 10.71M 11.17M 10.44M
Reconciled depreciation 0.93M 0.76M 0.91M 1.00M 0.51M
Ebit -5.96241M -4.33036M -5.82589M -2.37807M 0.14M
Ebitda -5.03093M -3.57163M -4.91560M -1.37814M 0.65M
Depreciation and amortization 0.93M 0.76M 0.91M 1.00M 0.51M
Non operating income net other - - - - -
Operating income -5.96241M -4.33036M -5.82589M -2.37807M -2.75944M
Other operating expenses 30.85M 24.66M 23.16M 20.34M 16.16M
Interest expense 0.07M 0.02M 0.02M 0.05M 0.03M
Tax provision 0.58M 0.69M 0.20M 0.49M 0.15M
Interest income 0.11M 0.09M 0.21M 0.28M 0.03M
Net interest income -0.15619M -0.08536M -0.01380M -0.02135M 0.08M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.58M 0.69M 0.20M 0.49M 0.15M
Total revenue 23.22M 17.70M 14.68M 14.08M 13.40M
Total operating expenses 23.41M 19.61M 19.20M 17.43M 13.20M
Cost of revenue 7.44M 5.04M 3.96M 2.91M 2.97M
Total other income expense net -0.06743M -0.01651M -0.01821M -0.04687M 2.88M
Discontinued operations - - - - -
Net income from continuing ops -6.61151M -5.04017M -6.04364M -2.91244M -0.03546M
Net income applicable to common shares -6.61152M -5.04017M -6.04364M -2.91244M -0.03546M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 45.91M 49.54M 55.74M 28.28M 32.53M
Intangible assets - 4.57M 4.56M 4.43M 4.28M
Earning assets - - - - -
Other current assets 0.45M 0.57M 0.39M 0.30M 0.25M
Total liab 13.65M 13.01M 12.67M 11.16M 9.32M
Total stockholder equity 32.26M 36.54M 43.07M 17.12M 23.20M
Deferred long term liab - 0.79M 0.79M 0.79M 0.79M
Other current liab 5.27M 3.33M 5.07M 2.24M 1.90M
Common stock 63.78M 63.42M 62.97M 31.63M 31.58M
Capital stock - 63.42M 62.97M 31.63M 31.58M
Retained earnings -34.65847M -29.07283M -21.57873M -15.65724M -8.86119M
Other liab - 0.95M 0.92M 0.92M 1.09M
Good will 0.90M 0.87M 0.87M 0.87M 0.87M
Other assets 0.00000M 0.64M 1.61M 1.98M 2.28M
Cash 11.73M 20.30M 29.25M 1.87M 12.66M
Cash and equivalents - - - - -
Total current liabilities 8.67M 7.94M 7.42M 5.68M 3.48M
Current deferred revenue 0.04M - - - -
Net debt -7.49913M -15.96459M -24.73949M 2.83M -7.73786M
Short term debt 0.21M 0.21M 0.18M 0.15M 0.17M
Short long term debt - - - - -
Short long term debt total 4.23M 4.33M 4.51M 4.71M 4.92M
Other stockholder equity - -1.05313M -3.66114M -4.19229M -4.84403M
Property plant equipment - 6.60M 6.25M 5.81M 6.28M
Total current assets 30.20M 36.87M 43.25M 15.98M 19.61M
Long term investments - - - - -
Net tangible assets - 31.89M 38.43M 12.61M 18.85M
Short term investments - - - - -
Net receivables 7.90M 7.71M 8.04M 8.84M 3.98M
Long term debt - - - - -
Inventory 10.12M 8.29M 5.51M 4.74M 2.50M
Accounts payable 3.15M 4.40M 2.17M 3.30M 1.41M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 3.14M 2.19M 1.67M 1.14M 0.49M
Additional paid in capital - - - - -
Common stock total equity - - - 31.63M 31.58M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.03M - - - 12.92M
Deferred long term asset charges - - - - -
Non current assets total 15.72M 12.67M 12.49M 12.30M 12.92M
Capital lease obligations - 4.33M 4.51M 4.71M 4.92M
Long term debt total - 4.12M 4.33M 4.56M 4.75M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -1.54840M -1.16102M -0.87419M -0.82049M -1.40311M
Change to liabilities 1.08M 1.82M 2.25M -1.34675M 1.43M
Total cashflows from investing activities -1.54840M -1.16102M -0.87419M -0.82049M -1.40311M
Net borrowings -0.28942M -0.28871M -0.28976M -0.61021M -0.05429M
Total cash from financing activities -0.72564M 30.17M -0.98596M 8.09M -0.35245M
Change to operating activities 0.74M 0.02M -3.12239M 0.18M -0.44895M
Net income -6.61151M -5.04017M -6.04364M -2.91244M -0.03546M
Change in cash -8.95308M 27.37M -10.78604M 6.81M -2.83472M
Begin period cash flow 29.25M 1.87M 12.66M 5.85M 8.69M
End period cash flow 20.30M 29.25M 1.87M 12.66M 5.85M
Total cash from operating activities -5.68003M -1.62941M -8.93487M -0.48934M -1.10733M
Issuance of capital stock - 33.00M - 9.78M -
Depreciation 0.93M 0.76M 0.91M 1.00M 0.51M
Other cashflows from investing activities - 0.00000M -0.34321M -0.34321M -0.59414M
Dividends paid -0.88259M -0.88132M -0.75242M -0.66050M 0.65M
Change to inventory -2.78129M -0.77536M -2.24057M 0.28M -0.09424M
Change to account receivables -0.58799M 0.69M -1.78310M 2.68M -0.74432M
Sale purchase of stock 0.00000M -1.65778M 0.00000M -0.41303M 0.00000M
Other cashflows from financing activities 0.16M -0.28871M -0.23354M -0.55123M 0.35M
Change to netincome 0.52M 0.75M 1.01M 0.40M -0.74711M
Capital expenditures 1.55M 1.16M 0.53M 0.48M 0.81M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.45M 0.40M 0.16M 0.03M 0.10M
Stock based compensation - - - - -
Other non cash items 5.68M 4.28M 5.13M 1.91M -0.47477M
Free cash flow -7.22843M -2.79043M -9.46585M -0.96662M -1.91631M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CYC
Cyclopharm Ltd		 - -% 1.35 - 116.28 6.63 3.30 5.79 -24.5712
COH
Cochlear Ltd		 -2.48 0.83% 296.93 53.21 47.17 8.48 10.35 8.40 32.43
PNV
Polynovo Ltd		 - -% 2.06 208.00 135.14 13.92 19.54 13.36 340.64
AVH
Avita Therapeutics Inc		 0.14 3.80% 3.82 - - 8.76 12.74 5.31 -10.0538
EBR
Ebr Systems Inc CDR		 0.01 1.48% 1.03 - - - 21.41 - -3.6785

Reports Covered

Stock Research & News

View All

Profile

Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally. The company operates through Technegas and Molecular Imaging segments. The Technegas segment offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism. This segment also distributes products to the diagnostic imaging sector. The Molecular Imaging segment provides radiopharmaceuticals that are used by physicians in the detection of cancer, neurological disorders, and cardiac diseases. The company serves nuclear medicine departments. Cyclopharm Limited was founded in 1986 and is headquartered in Kingsgrove, Australia.

Cyclopharm Ltd

1 The Crescent, Kingsgrove, NSW, Australia, 2208

Key Executives

Name Title Year Born
Mr. James S. McBrayer F.A.C.I.D., BSPharm, GDM, FAICD, AIM CEO, MD, Company Sec. & Director 1965
Mr. Mathew Farag Chief Operating Officer NA
Mr. Graham N. Phillips Fin. Mang. NA
Dr. Mark Doverty Global Head of Regulatory Compliance & Clinical Research NA
Ms. Sally-Ann Cornelius Head of Sales NA
Ms. Niamh McAree Head of Quality and Regulatory NA
Mr. Chris Quinn Head of Service NA
Ms. Sui Ling Cheah Financial Controller 1970
Mr. Lynn McLauchlin Gen. Mang. of Canada NA
Mr. Gary T. Somerville Quality & Regulatory Mang. NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.